Accumulating evidence has indicated that CAPN2, a calcium-activated protease, could participate in tumor progression and carcinogenesis in multiple cancer types including prostate cancer, ovarian cancer, breast cancer and hepatocellular carcinoma [16, 17, 20–22]. This evidence concerns the gene CAPN2 and breast cancer.